EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost‐effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO‐HCV trial

Aaron Guanliang Lim iD, Christer Frode Aas iD, Ege Su Çağlar, Jørn Henrik Vold, Lars Thore Fadnes, Peter Vickerman iD, Kjell Arne Johansson

Addiction · 2023

DOI: 10.1111/add.16305 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Addiction, 2023. Verfasst von Aaron Guanliang Lim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Substance Abuse, Intravenous, Hepatitis C, Chronic, Drug Users, Hepatitis C. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, Department of Health, Norges Forskningsråd.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims The INTRO‐HCV randomized controlled trial conducted in Norway over 2017–2019 found that integrated treatment, compared with standard‐of‐care hospital treatment, for hepatitis C virus (HCV) with direct‐acting antivirals (DAAs) improved treatment outcomes among people who inject drugs (PWID). We evaluated cost‐effectiveness of the INTRO‐HCV intervention.

Design

A Markov health state transition model of HCV disease progression and treatment with cost‐effectiveness analysis from the health‐provider perspective. Primary cost, utility, and health outcome data were derived from the trial. Costs and health benefits (quality‐adjusted life‐years, QALYs) were tracked over 50 years. Probabilistic and univariate sensitivity analyses investigated DAA price reductions and variations in HCV treatment and disease care cost assumptions, using costs from different countries (Norway, United Kingdom, United States, France, Australia). Setting and participants PWID attending community‐based drug treatment centers for people with opioid dependence in Norway.

Measurements

Incremental cost‐effectiveness ratio (ICER) in terms of cost per QALY gained, compared against a conventional (€70 000/QALY) willingness‐to‐pay threshold for Norway and lower (€20 000/QALY) threshold common among high‐income countries.

Findings

Integrated treatment resulted in an ICER of €13 300/QALY gained, with 99% and 71% probability of being cost‐effective against conventional and lower willingness‐to‐pay thresholds, respectively. A 30% lower DAA price reduced the ICER to €6 900/QALY gained, with 91% probability of being cost‐effective at the lower willingness‐to‐pay threshold. A 60% and 90% lower DAA price had 36% and >99% probability of being cost‐saving, respectively. Sensitivity analyses suggest integrated treatment was cost‐effective at the lower willingness‐to‐pay threshold (>60% probability) across different assumptions on HCV treatment and disease care costs with 30% DAA price reduction, and became cost‐saving with 60%–90% price reductions.

Conclusions

Integrated hepatitis C virus treatment for people who inject drugs in community settings is likely cost‐effective compared with standard‐of‐care referral pathways in Norway and may be cost‐saving in settings with particular characteristics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Substance Abuse, IntravenousHepatitis C, ChronicDrug UsersHepatitis CHumansHepacivirusCost-Benefit AnalysisAntiviral AgentsNorwayQuality-Adjusted Life Years

Stichwörter der Autor:innen

Markov modeldirect-acting antiviralshealth-related quality of lifeopiate substitution treatmentopioid agonist therapywillingness-to-pay

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
  • Bergen Addiction Research, Department of Addiction Medicine, Haukeland University Hospital, Bergen, Norway.
  • Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
  • Division of Psychiatry, Haukeland University Hospital, Bergen, Norway.

ORCID-Profile: Aaron Guanliang Lim, Christer Frode Aas, Peter Vickerman

Förderung

  • Wellcome Trust
  • Department of Health
  • Norges Forskningsråd
  • Helse Vest
  • Haukeland Universitetssjukehus
  • University of Bristol
  • NIHR Nottingham Biomedical Research Centre

Zitieren

APA

Lim, A. G., Aas, C. F., Çağlar, E. S., Vold, J. H., Fadnes, L. T., Vickerman, P., & Johansson, K. A. (2023). Cost‐effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO‐HCV trial. Addiction. https://doi.org/10.1111/add.16305

Vancouver

Lim AG, Aas CF, Çağlar ES, Vold JH, Fadnes LT, Vickerman P, et al. Cost‐effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO‐HCV trial. Addiction. 2023. doi:10.1111/add.16305

BibTeX
@article{Lim2023,
  author = {Lim, Aaron Guanliang and Aas, Christer Frode and Çağlar, Ege Su and Vold, Jørn Henrik and Fadnes, Lars Thore and Vickerman, Peter and Johansson, Kjell Arne},
  title = {Cost‐effectiveness of integrated treatment for hepatitis C virus (HCV) among people who inject drugs in Norway: An economic evaluation of the INTRO‐HCV trial},
  journal = {Addiction},
  year = {2023},
  doi = {10.1111/add.16305}
}
Kostenlos starten →